Physiological role and therapeutic target
The mechanism of action of this group of drugs is based on interference with a natural physiological process: enterohepatic circulation. Under normal conditions, the liver continuously synthesizes bile acids using endogenous cholesterol as the primary building material. The synthesized acids are secreted into the intestinal lumen, where they perform their function, after which the vast majority of them are reabsorbed and returned to the liver.
Bile acids located in the intestinal lumen serve as the main pharmacological target for sequestrants. By their chemical nature, drugs of this group are anion-exchange resins. Upon entering the gastrointestinal tract, they act exclusively locally. The resins bind free bile acids, forming large, insoluble, and non-absorbable complexes with them. As a result, normal recirculation is interrupted, and the bound acids leave the body, being excreted in the feces.
Compensatory response of hepatocytes
Massive loss of bile acids through the gastrointestinal tract triggers a powerful compensatory reaction by the liver. This process can be divided into several consecutive stages:
- The liver is forced to urgently increase the synthesis of bile acids de novo. For this biochemical process, hepatocytes begin to actively consume endogenous cholesterol.
- Intracellular cholesterol stores in liver cells are rapidly depleted.
- In response to the resulting deficiency, liver cells alter the structure of their membranes: the expression (total number) of specific LDL receptors on them significantly increases.
- Receptor-mediated endocytosis is enhanced — the process by which the liver actively captures atherogenic low-density lipoproteins (LDLs) from the systemic circulation.
The end result of this complex cascade is a pronounced decrease in the concentration of atherogenic lipoproteins in blood plasma. Notably, the level of high-density lipoproteins (HDLs) during such therapy either remains completely unchanged or shows a slight increase.
Drug representatives and clinical use
In clinical practice, the main representatives of the sequestrant group are cholestyramine (Questran) and colestipol (Colestid). Both medications have approximately the same therapeutic efficacy.
- Indications: The main indication for prescribing anion-exchange resins is type IIa hyperlipoproteinemia (HLP).
- Dosing regimen: The drugs are taken orally, 2–3 times a day. The standard course of treatment is 14 days.
- Temporal parameters of action: Initial lipid reduction is registered 24–48 hours after the start of therapy. The effect of a single dose lasts from 12 to 24 hours. Maximum clinical efficacy is achieved within one month. Even after complete discontinuation of the drug, the lipid-lowering aftereffect persists for 2–4 weeks.
Safety profile
Since bile acid sequestrants form non-absorbable complexes, their safety profile is quite specific. The vast majority of adverse reactions are associated with the local effect of resins on the gastrointestinal tract.
Patients most often complain of persistent constipation, nausea, heartburn, and marked flatulence. In some cases, therapy may be accompanied by a systemic reaction in the form of a headache.
Briefly: answers to topical questions
How do bile acid sequestrants affect the absorption of other drugs in the intestine?
Bile acid sequestrants can impair the absorption of concomitant drugs; when used concomitantly with a statin, the statin must be taken 1 hour before or 4 hours after the sequestrant.
How does long-term intake of bile acid sequestrants affect fat-soluble vitamin metabolism?
Taking bile acid sequestrants leads to impaired absorption of fat-soluble vitamins. The mechanism of this side effect is due to the binding of bile acids into insoluble complexes in the intestinal lumen. As a result, the patient may develop avitaminosis, in which a deficiency of the following substances occurs:
- Vitamin K — a decrease in its level increases the risk of bleeding.
- Vitamin E — is also subject to impaired absorption.
Imagine a sequestrant as a strict customs officer in the gut: it "confiscates" bile acids and exports them (in the feces). To mint new "currency", the liver has to break into its gold reserve — actively pulling cholesterol from the blood.
Class and exam questions
Why do sequestrants specifically lower blood LDL if they act exclusively in the intestine?
They bind bile acids in the intestine, causing the liver to experience an acute deficiency of them. To synthesize new acids de novo, hepatocytes are forced to take up cholesterol from the blood by capturing LDL via specific receptors.
Do anion-exchange resins affect "good" cholesterol (HDL) levels?
Practically none. While taking sequestrants, plasma HDL concentration either remains unchanged or shows only a slight increase.
How quickly does the effect of this group of drugs develop?
The initial effect appears after 24–48 hours, but the peak of therapeutic efficacy is achieved only after a month of regular intake.
What else to study on this topic
- The biochemical pathway of de novo bile acid synthesis from endogenous cholesterol
- Receptor-mediated endocytosis: structure and function of LDL receptors on the hepatocyte membrane
- Enterohepatic circulation: anatomy and physiology of the reabsorption process
- Type IIa hyperlipoproteinemia: pathogenesis, clinical presentation, and diagnostic criteria
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Bile Acid Sequestrants" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Drugs used in atherosclerosis"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.